Semaglutide
- Generic Name
- Semaglutide
- Brand Names
- Ozempic, Rybelsus, Wegovy
- Drug Type
- Small Molecule
- Chemical Formula
- C187H291N45O59
- CAS Number
- 910463-68-2
- Unique Ingredient Identifier
- 53AXN4NNHX
- Background
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity. Other members of this drug class include Exenatide and Liraglutide. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. Th...
- Indication
Semaglutide is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus, and is used as an adjunct to diet and exercise. However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis. Semaglutide is not in...
- Associated Conditions
- BMI >27 kg/m2, Cardiovascular Events, Obesity, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2014-05-26
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 38
- Registration Number
- NCT02147431
- Locations
- 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria
A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-05-23
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 44
- Registration Number
- NCT02146079
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1089
- Registration Number
- NCT02128932
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Taunton, United Kingdom
Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo
- Conditions
- Interventions
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 30
- Registration Number
- NCT02079870
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Leeds, United Kingdom
A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-02-25
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 52
- Registration Number
- NCT02070510
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2018-06-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 168
- Registration Number
- NCT02064348
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects
- First Posted Date
- 2014-02-12
- Last Posted Date
- 2017-03-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 7
- Registration Number
- NCT02060266
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2014-02-04
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 388
- Registration Number
- NCT02054897
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom
Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2013-12-27
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT02022254
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
- First Posted Date
- 2013-12-20
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 56
- Registration Number
- NCT02016911
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Bratislava, Slovakia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.